News

These data highlight the unique burdens faced by patients with generalized pustular psoriasis (GPP) compared to those of patients with psoriasis vulgaris.

A study suggests the prevalence of Legionella may explain why children with seasonal allergic rhinitis vs perennial allergic rhinitis have more severe symptoms.

Participants in a phase 3 OLE had a mean monthly attack rate of 0.08.

Teva and Medincell announced FDA acceptance of their sNDA for UZEDY, a risperidone extended-release injectable, to treat adults with bipolar I disorder.

These data provide a potential option for those suffering from hidradenitis suppurativa, as off-label treatment with botulinum toxin type X led to positive findings in patients.

Mepolizumab led to greater symptom score improvements than omalizumab in severe CRSwNP, though both biologics showed significant nasal polyp reduction.

In this quiz, we examine your knowledge of biologic therapy for the treatment of CRSwNP.

Positive 2-year results from the open-label compensated MASH cirrhosis arm of the MAESTRO-NAFLD-1 trial highlight resmetirom’s impact on liver stiffness.

On Feb. 26, 2025, Arcutis Biotherapeutics announced the FDA's acceptance of their sNDA for roflumilast cream 0.05% in AD for children aged 2 to 5 years.

Sebetralstat has a PDUFA date of June 12, 2025, for treating HAE in patients 12 years and older.

In this Diabetes Dialogue segment, hosts discussed the strengths of trial diversity and HbA1c reductions with automated insulin delivery in type 2 diabetes.

These data point to increasing omega-3 consumption as a potential preventive strategy against atopic dermatitis.

A novel fast-track protocol was linked to a lower incidence of delirium and reduced LOS after transplant without increasing rejection and readmission risk.

A new study presented at AAAAI 2025 linked pediatric obesity to a greater risk of developing allergic rhinitis, with a 1.24x increased risk at 1 year.

In this quiz, we test your knowledge of evidence-based use of intranasal corticosteroids for patients with CRSwNP.

The regulatory agency has set a PDUFA target action date of August 27, 2025, for the investigational gene therapy.

In this analysis, investigators sought evaluate the effectiveness and safety of adding low-dose oral minoxidil to the standard anti-inflammatory treatment of lichen planopilaris.

Despite decreasing death rates, an analysis of GBD 2021 data highlights the increasing incidence of cirrhosis and other chronic liver diseases.

Afif El-Hasan, MD of Kaiser Permanente in California joins host Albert Rizzo, MD, to discuss the acute effects of wildfire smoke on air quality.

Three subgroup analyses of the phase 3 NAVIGATOR study are set to be presented at the AAAAI/WAO Joint Congress.

Phase 3 ANCHOR-1/2 data support depemokimab as a twice-yearly treatment for CRSwNP, effectively reducing blood eosinophil counts over 52 weeks.

Eyelid pressure patching concomitantly with a decellularized, dehydrated amniotic membrane could prove a novel method to address PCED.

An audio recap of the top 5 stories in healthcare news from the week of 02/16 - 02/23.

These data suggest that psoriasis treatment algorithms may benefit younger patients if they implement a step-down rather than step-up approach to biologic use.

A real-world analysis found mepolizumab significantly improved symptoms in CRSwNP patients, reducing SNOT-22 scores, oral corticosteroid use, and surgery rates.

HCV screening in pregnant women increased following universal screening guidelines, but the proportion of women who were ever tested remained low.

Ahead of AAAAI 2025, HCPLive spoke with Jaroenpuntaruk about varying hypersensitivity reactions in patients with atopic diseases on biologics.

Epioxa has been assigned a target action date of October 20, 2025, for the regulatory agency’s review of the NDA.